

Theodoros P Vassilakopoulos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1804541/publications.pdf>

Version: 2024-02-01

256
papers

5,114
citations

126907

33
h-index

118850

62
g-index

256
all docs

256
docs citations

256
times ranked

6789
citing authors

#	ARTICLE	IF	CITATIONS
1	Genotype-Phenotype Relationships in Inheritable Idiopathic Pulmonary Fibrosis: A Greek National Cohort Study. <i>Respiration</i> , 2022, 101, 531-543.	2.6	5
2	The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study. <i>Cancers</i> , 2022, 14, 791.	3.7	2
3	TRPV4 Inhibition Exerts Protective Effects Against Resistive Breathing Induced Lung Injury. <i>International Journal of COPD</i> , 2022, Volume 17, 343-353.	2.3	2
4	Serum ferritin levels in previously untreated classical Hodgkin lymphoma: correlations and prognostic significance. <i>Leukemia and Lymphoma</i> , 2022, 63, 799-812.	1.3	5
5	Very Early Onset of Therapy-Related Acute Myeloid Leukemia with 11q23 Rearrangement Presenting with Unusual PET Findings after R-DA-EPOCH for Primary Mediastinal Large B-Cell Lymphoma. <i>Medicina (Lithuania)</i> , 2022, 58, 48.	2.0	2
6	Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab. <i>Cancers</i> , 2022, 14, 1917.	3.7	9
7	Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma. <i>In Vivo</i> , 2022, 36, 1302-1315.	1.3	2
8	Symptomatic ovarian involvement as the initial presentation of primary mediastinal large b-cell lymphoma. <i>Gynecologic Oncology Reports</i> , 2022, 41, 100988.	0.6	0
9	Very late relapses in Hodgkin lymphoma treated with chemotherapy with or without radiotherapy: linear pattern and distinct prognostic factors. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	5
10	Curative surgery in highly selected patients with heavily pretreated, relapsed/refractory classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 722-726.	1.3	1
11	Development of Classic Hodgkin Lymphoma after successful treatment of primary mediastinal large b-cell lymphoma: results from a well-defined database. <i>Leukemia Research</i> , 2021, 100, 106479.	0.8	3
12	Successful salvage of primary progressive Hodgkin lymphoma with the combination of post-transplant brentuximab vedotin and radiotherapy: Combining novelty and tradition. <i>Hematological Oncology</i> , 2021, 39, 258-262.	1.7	3
13	Modulation of IL-6/STAT3 signaling axis in CD4+FOXP3 ^{hi} T cells represents a potential antitumor mechanism of azacitidine. <i>Blood Advances</i> , 2021, 5, 129-142.	5.2	7
14	Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes. <i>Blood Cancer Journal</i> , 2021, 11, 30.	6.2	2
15	Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies. <i>Annals of Hematology</i> , 2021, 100, 2279-2292.	1.8	10
16	Expression of the novel tumour suppressor sterile alpha motif and HD domain-containing protein 1 is an independent adverse prognostic factor in classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2021, 193, 488-496.	2.5	12
17	Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas. <i>Hematological Oncology</i> , 2021, 39, 336-348.	1.7	25
18	Rapidly deteriorating B-CLL at presentation: clonally related Burkitt leukemia as an atypical Richter transformation?. <i>Blood</i> , 2021, 137, 2272-2272.	1.4	3

#	ARTICLE	IF	CITATIONS
19	Relapsed or refractory classical Hodgkin lymphoma: which immunotherapy, and when?. <i>Lancet Oncology</i> , The, 2021, 22, 417-419.	10.7	4
20	Pancytopenia, eosinophilia and coagulation disorders in a patient with Tâ€acute lymphoblastic leukemia in prolonged remission. <i>American Journal of Hematology</i> , 2021, 96, 632-637.	4.1	1
21	Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP. <i>Oncologist</i> , 2021, 26, 597-609.	3.7	15
22	Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study. <i>Journal of Hematology and Oncology</i> , 2021, 14, 111.	17.0	11
23	Progressive Multifocal Leukoencephalopathy Following Treatment With Obinutuzumab in a Patient With Non-Hodgkin Follicular Lymphoma: A Case Report. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e601-e605.	0.4	1
24	Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.4	5
25	TACI Mutations in Primary Antibody Deficiencies: A Nationwide Study in Greece. <i>Medicina (Lithuania)</i> , 2021, 57, 827.	2.0	6
26	Subdiaphragmatic extranodal localizations at diagnosis of primary mediastinal large B-cell lymphoma: an impressive, rare presentation with no independent effect on prognosis. <i>Leukemia Research</i> , 2021, 107, 106595.	0.8	3
27	Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study. <i>Cancers</i> , 2021, 13, 4480.	3.7	44
28	CD56 expression in multiple myeloma: Correlation with poor prognostic markers but no effect on outcome. <i>Pathology Research and Practice</i> , 2021, 225, 153567.	2.3	11
29	Paraneoplastic Intrahepatic Cholestasis in Supradiaphragmatic Classical Hodgkin Lymphoma Successfully Treated With Brentuximab Vedotin: A Case Report and Review of the Literature. <i>In Vivo</i> , 2021, 35, 1951-1957.	1.3	2
30	Pembrolizumab-induced Remission After Failure of Axicabtagene Ciloleucel: Case Report and Literature Review. <i>In Vivo</i> , 2021, 35, 3401-3406.	1.3	4
31	Myelodysplastic Syndromes (MDS) Presenting with Isolated Thrombocytopenia: Characteristics, Outcomes, and Clinical Presentation Differences from Immune Thrombocytopenic Purpura (ITP). <i>Blood</i> , 2021, 138, 1535-1535.	1.4	3
32	Five-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL). <i>Blood</i> , 2021, 138, 1366-1366.	1.4	20
33	Poor Neutralizing Antibody Responses in Patients with CLL, NHL and HL after Vaccination Against Sars-Cov-2; A Prospective Study in 132 Patients. <i>Blood</i> , 2021, 138, 3752-3752.	1.4	0
34	Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.4	1
35	Effectiveness of 5-Azacitidine in older patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia: A retrospective analysis of the Hellenic (Greek) MDS Study Group. <i>Journal of Geriatric Oncology</i> , 2020, 11, 121-124.	1.0	5
36	Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 950-954.	1.3	13

#	ARTICLE	IF	CITATIONS
37	Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective. <i>BMC Cancer</i> , 2020, 20, 1088.	2.6	12
38	<p>Spontaneous Breathing Through Increased Airway Resistance Augments Elastase-Induced Pulmonary Emphysema</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 1679-1688.	2.3	6
39	Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072096612.	2.5	9
40	How to ventilate obstructive and asthmatic patients. <i>Intensive Care Medicine</i> , 2020, 46, 2436-2449.	8.2	25
41	What's new about pulmonary hyperinflation in mechanically ventilated critical patients. <i>Intensive Care Medicine</i> , 2020, 46, 2381-2384.	8.2	6
42	Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e511-e522.	4.6	201
43	Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes. <i>Hematological Oncology</i> , 2020, 38, 541-553.	1.7	3
44	Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072090291.	2.5	21
45	Validation of the simplified International Prognostic Score3 in a Hellenic cohort of patients with advanced-stage Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2020, 190, e335-e339.	2.5	4
46	Risk factors for cardiovascular disease mortality in patients with myelodysplastic syndromes: A nationwide, registry-based cohort study. <i>EJHaem</i> , 2020, 1, 255-261.	1.0	2
47	Senescence and senotherapeutics: a new field in cancer therapy. , 2019, 193, 31-49.		116
48	Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. <i>Blood</i> , 2019, 134, 1144-1153.	1.4	255
49	Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies. <i>Cancers</i> , 2019, 11, 1071.	3.7	32
50	A Unique Case of Primary Extranodal Marginal Zone Lymphoma of the Anal Canal. <i>Acta Haematologica</i> , 2019, 142, 87-91.	1.4	4
51	Differential regulation of myofibrillar proteins in skeletal muscles of septic mice. <i>Physiological Reports</i> , 2019, 7, e14248.	1.7	17
52	Azacitidine failure revisited: an appraisal based on real life data from the MDS registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS).. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019045.	1.3	5
53	Regulation of breathing pattern by IL-10. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2019, 317, R190-R202.	1.8	7
54	Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in "Real-Life" Outside of Clinical Trials. <i>Anticancer Research</i> , 2019, 39, 2591-2598.	1.1	2

#	ARTICLE	IF	CITATIONS
55	Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome. <i>Annals of Hematology</i> , 2019, 98, 1383-1392.	1.8	9
56	Central nervous system involvement in primary bone marrow or splenic marginal zone lymphoma: Report of two cases and review of the literature. <i>Hematological Oncology</i> , 2019, 37, 219-222.	1.7	4
57	Effect of Prior Therapy on the Efficacy and Safety of Oral Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Study. <i>Blood</i> , 2019, 134, 5333-5333.	1.4	1
58	Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 240-240.	1.4	20
59	Treatment of Hodgkin Lymphoma – New and Developing Therapies and Their Potential Role in Standard of Care. <i>European Oncology and Haematology</i> , 2019, 15, 53.	0.0	1
60	The Prognostic Significance of Monocytopenia in Patients with Myelodysplastic Syndrome. <i>Blood</i> , 2019, 134, 5427-5427.	1.4	0
61	Estimated Glomerular Filtration Rate Is an Independent Predictor of Outcome in High-Risk Myelodysplastic Syndrome (MDS) and Low Blast Count Acute Myeloid Leukaemia (AML) Patients Treated with Azacytidine (AZA). a Retrospective Study from the MDS Registry of the Hellenic MDS Study Group. <i>Blood</i> , 2019, 134, 5423-5423.	1.4	0
62	Prognostic Significance of Bone Marrow Cellularity in the Outcome of Patients with Myelodysplastic Syndromes Treated with Azacytidine: A Retrospective Analysis from the Hellenic MDS Study Group. <i>Blood</i> , 2019, 134, 5417-5417.	1.4	0
63	Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece. <i>Blood</i> , 2019, 134, 5340-5340.	1.4	1
64	Modulation of the IL-6/STAT3 Signaling Axis in CD4+ T Cells As a Potential Immune Mechanism of Action of Azacytidine in High-Risk Myelodysplastic Syndromes. <i>Blood</i> , 2019, 134, 2988-2988.	1.4	0
65	Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study. <i>Blood</i> , 2019, 134, 4124-4124.	1.4	0
66	Successful reversal of severe liver function impairment with Brentuximab vedotin in multiply relapsed/refractory classical Hodgkin lymphoma. <i>Jbuon</i> , 2019, 24, 2483-2489.	0.3	2
67	The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group. <i>American Journal of Hematology</i> , 2018, 93, 895-901.	4.1	10
68	Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases. <i>European Respiratory Journal</i> , 2018, 51, 1700745.	6.7	136
69	Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience. <i>Hematological Oncology</i> , 2018, 36, 174-181.	1.7	15
70	Bone metabolism markers and angiogenic cytokines as regulators of human hematopoietic stem cell mobilization. <i>Journal of Bone and Mineral Metabolism</i> , 2018, 36, 399-409.	2.7	3
71	Should rituximab replace splenectomy in the management of splenic marginal zone lymphoma?. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 65-72.	1.7	11
72	Study of bone metabolism and angiogenesis in patients undergoing high-dose chemotherapy/autologous hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2018, 100, 131-139.	2.2	1

#	ARTICLE	IF	CITATIONS
73	Non-Inherited Maternal Antigens Identify Acceptable HLA Mismatches: A New Policy for the Hellenic Cord Blood Bank. <i>Bioengineering</i> , 2018, 5, 77.	3.5	3
74	Prediction of dysnatremias in critically ill patients based on the law of conservation of mass. Comparison of existing formulae. <i>PLoS ONE</i> , 2018, 13, e0207603.	2.5	5
75	The Role of 18FDG-PET/CT in Malignant Lymphomas: Clinical Implications. , 2018, , 619-647.		0
76	Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group. <i>Leukemia Research</i> , 2018, 71, 55-59.	0.8	0
77	p38 Inhibition Ameliorates Inspiratory Resistive Breathing-Induced Pulmonary Inflammation. <i>Inflammation</i> , 2018, 41, 1873-1887.	3.8	3
78	The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group. <i>Hematological Oncology</i> , 2018, 36, 693-700.	1.7	14
79	Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis. <i>Hematological Oncology</i> , 2018, 36, 645-650.	1.7	6
80	Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance. <i>Blood</i> , 2018, 132, 666-670.	1.4	44
81	Two-Year Follow-up of Keynote-087 Study: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 2900-2900.	1.4	13
82	Systemic Mastocytosis: Management and Outcome. Data Analysis from the Greek Registry. <i>Blood</i> , 2018, 132, 5463-5463.	1.4	0
83	Thioredoxin-1, chemokine (C-X-C motif) ligand-9 and interferon- γ expression in the neoplastic cells and macrophages of Hodgkin lymphoma: clinicopathologic correlations and potential prognostic implications. <i>Leukemia and Lymphoma</i> , 2017, 58, 2227-2239.	1.3	4
84	Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece. <i>Clinical Drug Investigation</i> , 2017, 37, 833-844.	2.2	13
85	Recurrent acute myopericarditis without effusion during ATRA induction and ATO salvage of APL: a variant form of the differentiation syndrome?. <i>Leukemia and Lymphoma</i> , 2017, 58, 1743-1746.	1.3	5
86	Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies. <i>European Journal of Haematology</i> , 2017, 99, 409-414.	2.2	37
87	Treatment of splenic marginal zone lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2017, 30, 139-148.	1.7	23
88	Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 1506-1508.	1.3	9
89	Detection of L265P <i>MYD88</i> mutation in a series of clonal B-cell lymphocytosis of marginal zone origin (CBLMZ). <i>Hematological Oncology</i> , 2017, 35, 542-547.	1.7	10
90	Direct and Indirect Costs of Asthma Management in Greece: An Expert Panel Approach. <i>Frontiers in Public Health</i> , 2017, 5, 67.	2.7	15

#	ARTICLE	IF	CITATIONS
91	Chronic obstructive pulmonary disease with mild airflow limitation: current knowledge and proposal for future research – a consensus document from six scientific societies. International Journal of COPD, 2017, Volume 12, 2593-2610.	2.3	44
92	The direct and indirect costs of managing chronic obstructive pulmonary disease in Greece. International Journal of COPD, 2017, Volume 12, 1395-1400.	2.3	28
93	The role of Src & ERK1/2 kinases in inspiratory resistive breathing induced acute lung injury and inflammation. Respiratory Research, 2017, 18, 209.	3.6	12
94	Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. Journal of Clinical Oncology, 2017, 35, 2125-2132.	1.6	830
95	Tumor Protein 53 Gene Mutations Without 17p13 Deletion Have No Significant Clinical Implications in Chronic Lymphocytic Leukemia. Detection of a New Mutation. Anticancer Research, 2017, 37, 2387-2391.	1.1	2
96	The Significance of PET/CT in the Initial Staging of Hodgkin Lymphoma: Experience Outside Clinical Trials. , 2017, 37, 5727-5736.		13
97	The differential effects of inspiratory, expiratory, and combined resistive breathing on healthy lung. International Journal of COPD, 2016, Volume 11, 1623-1638.	2.3	11
98	Can resistive breathing injure the lung? Implications for COPD exacerbations. International Journal of COPD, 2016, Volume 11, 2377-2384.	2.3	8
99	Current and emerging treatment approaches for splenic marginal zone lymphoma. Expert Opinion on Orphan Drugs, 2016, 4, 897-905.	0.8	1
100	Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. Blood, 2016, 128, 2666-2670.	1.4	82
101	Recent Advances in Aggressive Large B-cell Lymphomas: A Comprehensive Review. Advances in Anatomic Pathology, 2016, 23, 202-243.	4.3	15
102	Prognostic factors in Hodgkin lymphoma. Seminars in Hematology, 2016, 53, 155-164.	3.4	37
103	No evidence of splenic disease in patients with splenic marginal zone lymphoma undergoing splenectomy for autoimmune hemolytic anemia after monotherapy with rituximab. Leukemia and Lymphoma, 2016, 57, 2705-2708.	1.3	5
104	PET/CT in Hodgkin Lymphoma. , 2016, , 51-107.		0
105	Aggressive B-Cell Lymphomas. , 2016, , 111-171.		0
106	HD2000 Update in Hodgkin Lymphoma"ABVD or BEACOPP?. Journal of Clinical Oncology, 2016, 34, 3584-3585.	1.6	1
107	Hodgkin lymphoma: Introduction. Seminars in Hematology, 2016, 53, 137-138.	3.4	1
108	Prognostic significance of signal transducer and activator of transcription 5 and 5b expression in Epstein"Barr virus"positive patients with chronic lymphocytic leukemia. Cancer Medicine, 2016, 5, 2240-2248.	2.8	8

#	ARTICLE	IF	CITATIONS
109	Potential role of AKT/mTOR signalling proteins in hairy cell leukaemia: association with BRAF/ERK activation and clinical outcome. <i>Scientific Reports</i> , 2016, 6, 21252.	3.3	6
110	Treatment of advanced-stage Hodgkin lymphoma. <i>Seminars in Hematology</i> , 2016, 53, 171-179.	3.4	22
111	Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens. <i>Oncologist</i> , 2016, 21, 343-353.	3.7	24
112	The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine. <i>Clinical Cancer Research</i> , 2016, 22, 1958-1968.	7.0	16
113	Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study. <i>Blood</i> , 2016, 128, 1107-1107.	1.4	36
114	Validation of the Revised International Prognostic Scoring System in 2582 Patients with Myelodysplastic Syndrome: A Multicenter Study By the Hellenic MDS Study Group. <i>Blood</i> , 2016, 128, 2004-2004.	1.4	0
115	17p11.31 Deletions: A Novel Marker of Clinical Aggressiveness in Primary Mediastinal B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 609-609.	1.4	0
116	Comment on "Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial". <i>Haematologica</i> , 2015, 100, e480-e481.	3.5	4
117	Multifocal Bilateral Breast Cancer and Breast Follicular Lymphoma: A Simple Coincidence?. <i>Journal of Breast Cancer</i> , 2015, 18, 296.	1.9	7
118	Functional p53 can modulate the relationship between E2F-1 expression and tumor kinetics in Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 748-754.	1.3	4
119	Inspiratory resistive breathing induces MMP-9 and MMP-12 expression in the lung. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2015, 308, L683-L692.	2.9	15
120	Significance of the detection of paroxysmal nocturnal hemoglobinuria clones in patients with multiple myeloma undergoing autologous stem cell transplantation. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2015, 8, 150-159.	0.9	6
121	Role of FDG-PET/CT in staging and first-line treatment of Hodgkin and aggressive B-cell lymphomas. <i>Memo - Magazine of European Medical Oncology</i> , 2015, 8, 105-114.	0.5	6
122	Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) with concurrent high grade component at diagnosis: clinico-pathologic features and treatment strategy. <i>Leukemia and Lymphoma</i> , 2015, 56, 3230-3232.	1.3	1
123	A PET-avid lymphoma in primary mediastinal large B-cell lymphoma: positive or negative, and how to handle it in the end. <i>Leukemia and Lymphoma</i> , 2015, 56, 3-5.	1.3	11
124	New Insights in the Mobilization of Hematopoietic Stem Cells in Lymphoma and Multiple Myeloma Patients. <i>BioMed Research International</i> , 2014, 2014, 1-11.	1.9	19
125	Immunohistochemical Analysis of IL-6, IL-8/CXCR2 Axis, and SOCS-3 in Lymph Nodes from Patients with Chronic Lymphocytic Leukemia: Correlation between Microvascular Characteristics and Prognostic Significance. <i>BioMed Research International</i> , 2014, 1-13.	1.9	17
126	New Insights into Monoclonal B-Cell Lymphocytosis. <i>BioMed Research International</i> , 2014, 2014, 1-11.	1.9	17

#	ARTICLE	IF	CITATIONS
127	Evidence for regulation of oxidative stress by latent membrane protein 1 oncoprotein in patients with low-grade leukemic B cell lymphoma with latent Epstein-Barr virus infection. <i>Leukemia and Lymphoma</i> , 2014, 55, 1904-1909.	1.3	3
128	Prognostic significance of immunohistochemical expression of the angiogenic molecules vascular endothelial growth factor-A, vascular endothelial growth factor receptor-1 and vascular endothelial growth factor receptor-2 in patients with classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 558-564.	1.3	20
129	Defining a training framework for clinicians in respiratory critical care. <i>European Respiratory Journal</i> , 2014, 44, 572-577.	6.7	5
130	Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?. <i>Leukemia and Lymphoma</i> , 2014, 55, 1463-1470.	1.3	37
131	Nodal marginal zone lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 1240-1250.	1.3	20
132	Survivin Messenger RNA Levels in Epstein-Barr Virus-Positive Patients With Leukemic Low-Grade B-Cell Lymphomas Expressing the Latent Membrane Protein 1: Evidence of Apoptotic Function?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 56-60.	0.4	2
133	Validation of the simplified prognostic score for splenic marginal zone lymphoma of the Splenic Marginal Zone Lymphoma Working Group. <i>Leukemia and Lymphoma</i> , 2014, 55, 2640-2642.	1.3	16
134	Clinical Aspects of Malt Lymphomas. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 262-272.	2.3	17
135	Apoptotic and proliferative characteristics of proliferation centers in lymph node sections of patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 571-582.	1.3	7
136	Pure red cell aplasia complicating the course of long-standing mantle cell lymphoma. <i>International Journal of Hematology</i> , 2014, 99, 777-781.	1.6	1
137	c-JUN N-terminal kinase (JNK) is activated and contributes to tumor cell proliferation in classical Hodgkin lymphoma. <i>Human Pathology</i> , 2014, 45, 565-572.	2.0	24
138	Clonal B-cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal-zone origin: is this a distinct entity?. <i>Blood</i> , 2014, 123, 1199-1206.	1.4	76
139	Clinical Implications of the Role of 18FDG-PET/CT in Malignant Lymphomas. , 2014, , 249-265.		1
140	Hypercalcemia Remains an Adverse Prognostic Factor for Newly Diagnosed Patients with Symptomatic Multiple Myeloma in the Era of Novel Anti-Myeloma Therapies, Independently of Age, ISS Stage and Treatment Type: An Analysis of 2129 Patients. <i>Blood</i> , 2014, 124, 2113-2113.	1.4	3
141	Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment. <i>Blood</i> , 2014, 124, 4769-4769.	1.4	1
142	The presence of CD55- and/or CD59-deficient erythrocytic populations in patients with rheumatic diseases reflects an immune-mediated bone-marrow derived phenomenon. <i>Medical Science Monitor</i> , 2014, 20, 123-139.	1.1	12
143	Aberrant Immunoglobulin Variations as Indicators of Eventual Clonal Changes in Symptomatic Multiple Myeloma Patients' Course. <i>Current Cancer Therapy Reviews</i> , 2014, 10, 90-96.	0.3	0
144	Composite Lymphomas: A Challenging Entity. <i>Current Cancer Therapy Reviews</i> , 2014, 10, 80-89.	0.3	0

#	ARTICLE	IF	CITATIONS
145	CD4+ T Cells in High-Risk MDS Patients Bear an Aberrant STAT Signaling Biosignature. <i>Blood</i> , 2014, 124, 1906-1906.	1.4	0
146	Gastric involvement in patients with primary mediastinal large B-cell lymphoma. <i>Anticancer Research</i> , 2014, 34, 6717-23.	1.1	6
147	Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab. <i>Hematological Oncology</i> , 2013, 31, 10-17.	1.7	30
148	Advanced and Relapsed/Refractory Hodgkin Lymphoma: What Has Been Achieved During the Last 50 Years. <i>Seminars in Hematology</i> , 2013, 50, 4-14.	3.4	25
149	A comprehensive immunohistochemical approach of AKT/mTOR pathway and p-STAT3 in mycosis fungoides. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 375-384.	1.2	20
150	Safety and efficacy of 5-azacytidine treatment in myelodysplastic syndrome patients with moderate and mild renal impairment. <i>Leukemia Research</i> , 2013, 37, 889-893.	0.8	13
151	Correlation of Fc γ 3 RIIA polymorphisms with latent Epstein-Barr virus infection and latent membrane protein 1 expression in patients with low grade B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2013, 54, 2030-2034.	1.3	16
152	Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents. <i>Hematological Oncology</i> , 2013, 31, 96-102.	1.7	55
153	Treatment of Splenic Marginal Zone Lymphoma With Rituximab Monotherapy: Progress Report and Comparison With Splenectomy. <i>Oncologist</i> , 2013, 18, 190-197.	3.7	77
154	Expression Of CD25 Antigen On CD34+ Cells Is An Independent Predictor Of Survival In Late Stage MDS Patients Treated With Azacitidine. <i>Blood</i> , 2013, 122, 1508-1508.	1.4	0
155	Distinct Profile and Epigenetic Modulation Of STAT Signaling In FOXP3+ T Regulatory Cells Among The Various MDS Subtypes. <i>Blood</i> , 2013, 122, 1509-1509.	1.4	0
156	Evaluation Of Immunoglobulin Variations (Clonal Changes) In Symptomatic Multiple Myeloma (MM) Patients' Course. <i>Blood</i> , 2013, 122, 3173-3173.	1.4	0
157	The Presence Of Spine Bone Plasmacytomas At The Time Of Multiple Myeloma (MM) Diagnosis Confers Poor Prognosis. <i>Blood</i> , 2013, 122, 5366-5366.	1.4	0
158	Presence Of CD55- and/Or CD59-Deficient Erythrocytes In Patients With Rheumatic Diseases: An Immune-Mediated Phenomenon?. <i>Blood</i> , 2013, 122, 3429-3429.	1.4	0
159	Omitting or reducing radiotherapy in childhood or adolescence Hodgkin Lymphoma. <i>Translational Pediatrics</i> , 2013, 2, 126-30.	1.2	2
160	Rituximab in the treatment of EBV-positive low grade B-cell lymphoma. <i>Anticancer Research</i> , 2013, 33, 5693-8.	1.1	2
161	Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone with or Without Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma: The Emerging Standard of Care. <i>Oncologist</i> , 2012, 17, 239-249.	3.7	105
162	Autoimmune hemolytic anemia and autoimmune thrombocytopenia at diagnosis and during follow-up of Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 1481-1487.	1.3	21

#	ARTICLE	IF	CITATIONS
163	Significance of Serum Free Light Chains in Chronic Lymphocytic Leukemia (cLL) Prognosis. <i>Blood</i> , 2012, 120, 4568-4568.	1.4	1
164	Increased Serum Transforming Growth Factor-beta1 (Tgf-beta1) Is Related to a Better Outcome in MM, WM and CLL Patients. <i>Blood</i> , 2012, 120, 4976-4976.	1.4	1
165	Impact of Novel M-Component Based Biomarkers On to Progression Free Survival After Treatment in Intact Immunoglobulin Multiple Myeloma.. <i>Blood</i> , 2012, 120, 2927-2927.	1.4	0
166	A Shorter Time to First Treatment and Worst Overall survival Is Observed in Cll Patients with Reduced Serum IgM As Evaluated with Novel Serum Immunoassays. <i>Blood</i> , 2012, 120, 4585-4585.	1.4	0
167	The Levels of a G-CSF-Inducible pSTAT3+pSTAT5+ Subpopulation of MDS Progenitors with Leukemic Stem Cell Phenotype Predict the Response to Azacytidine. <i>Blood</i> , 2012, 120, 3795-3795.	1.4	0
168	A Comprehensive Immunohistochemical Approach of AKT/mTOR Pathway and p-STAT3 in Mycosis Fungoides.. <i>Blood</i> , 2012, 120, 2663-2663.	1.4	0
169	Lower Levels of Survivin in Patients with Leukemic Low Grade B-Cell Lymphomas Expressing LMP1 Oncoprotein of Epstein-Barr Virus. <i>Blood</i> , 2012, 120, 1560-1560.	1.4	0
170	Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen. <i>Leukemia and Lymphoma</i> , 2011, 52, 387-393.	1.3	35
171	Three-Dimensional Imaging of a Ductus Arteriosus Aneurysm in an Adult. <i>Annals of Thoracic Surgery</i> , 2011, 91, 931.	1.3	1
172	Correlation of Fc Gamma RIIA Polymorphisms with EBV-Positivity and LMP1 Expression in Patients with Low Grade B-Cell Lymphomas. <i>Blood</i> , 2011, 118, 1600-1600.	1.4	12
173	Regulation of Apoptosis and Oxidative Stress by LMP1 Oncoprotein of Epstein-Barr Virus in Patients with Low Grade B-Cell Leukemic Lymphomas. <i>Blood</i> , 2011, 118, 5212-5212.	1.4	0
174	Chronic Lymphocytic Leukemia: Proliferative and Apoptotic Profile on Lymph Node, Studied by Immunohistochemistry Including the Proliferation Centers. <i>Blood</i> , 2011, 118, 2538-2538.	1.4	0
175	Determination of the Percentage of CML Patients that Achieve Continuous Complete Molecular Response Under Treatment with TKIs and Are Eligible for Participation in a TKI Discontinuation Study. <i>Blood</i> , 2011, 118, 4446-4446.	1.4	0
176	Treatment of Splenic Marginal Zone Lymphoma with Rituximab Monotherapy in 59 Patients. <i>Blood</i> , 2011, 118, 2712-2712.	1.4	2
177	Immunohistochemical expression and prognostic significance of CCND3, MCM2 and MCM7 in Hodgkin lymphoma. <i>Anticancer Research</i> , 2011, 31, 3585-94.	1.1	24
178	Kikuchi's lymphadenopathy: a relatively rare but important cause of lymphadenopathy in Greece, potentially associated with the antiphospholipid syndrome. <i>Rheumatology International</i> , 2010, 30, 925-932.	3.0	11
179	Incorporating novel agents in the treatment of myelodysplastic syndromes. <i>Leukemia Research</i> , 2010, 34, 6-17.	0.8	10
180	A Novel Immunological Assay for Hepcidin Quantification in Human Serum. <i>PLoS ONE</i> , 2009, 4, e4581.	2.5	72

#	ARTICLE	IF	CITATIONS
181	Disease-Related Anemia in Chronic Lymphocytic Leukemia Is Not Due to Intrinsic Defects of Erythroid Precursors: A Possible Pathogenetic Role for Tumor Necrosis Factor-Alpha. <i>Acta Haematologica</i> , 2009, 121, 187-195.	1.4	25
182	Early-Stage Gastric MALT Lymphoma: Is It a Truly Localized Disease?. <i>Oncologist</i> , 2009, 14, 148-154.	3.7	13
183	The Patient-Ventilator Interaction Has a Third Player. <i>Chest</i> , 2009, 136, 957-959.	0.8	4
184	First-Line Chemotherapy Leads to High Bone Turnover and Reduced Bone Mass in Patients with Non-Hodgkin's Lymphoma (NHL).. <i>Blood</i> , 2009, 114, 1951-1951.	1.4	1
185	Increased Immunohistochemical CD138 Expression in Waldenström's Macroglobulinemia (WM) in Comparison with Splenic Marginal Zone Lymphoma (SMZL).. <i>Blood</i> , 2009, 114, 5008-5008.	1.4	1
186	CD4(+)/CD56(+) Hematodermic (plasmacytoid dendritic cell) Tumor: a Highly Proliferating Neoplasm with Aberrant Expression of Immunohistochemical Markers and Poor Outcome.. <i>Blood</i> , 2009, 114, 2930-2930.	1.4	0
187	Mutation analysis of IgVH genes in splenic marginal zone lymphomas: correlation with clinical characteristics and outcome. <i>Anticancer Research</i> , 2009, 29, 1811-6.	1.1	11
188	Understanding wasted/ineffective efforts in mechanically ventilated COPD patients using the Campbell diagram. <i>Intensive Care Medicine</i> , 2008, 34, 1336-1339.	8.2	22
189	Safety and Efficacy of Low-Dose Bexarotene and PUVA in the Treatment of Patients with Mycosis Fungoides. <i>American Journal of Clinical Dermatology</i> , 2008, 9, 169-173.	6.7	34
190	Non-gastric extra-nodal marginal zone lymphomas—a single centre experience on 76 patients. <i>Leukemia and Lymphoma</i> , 2008, 49, 2308-2315.	1.3	32
191	Topoisomerase III \pm Expression as an Independent Prognostic Factor in Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2008, 14, 1759-1766.	7.0	24
192	Outcome and toxicity in relapsed hairy cell leukemia patients treated with rituximab. <i>Leukemia and Lymphoma</i> , 2008, 49, 1817-1820.	1.3	17
193	Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib. <i>Haematologica</i> , 2008, 93, 451-454.	3.5	27
194	Nitric oxide production in the ventilatory muscles in response to acute resistive loading. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2007, 292, L1013-L1022.	2.9	10
195	Ventilatory muscle activation and inflammation: cytokines, reactive oxygen species, and nitric oxide. <i>Journal of Applied Physiology</i> , 2007, 102, 1687-1695.	2.5	23
196	Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. <i>British Journal of Haematology</i> , 2007, 137, 240-243.	2.5	108
197	The Addition of sFLCR Improves ISS Prognostication in Multiple Myeloma (MM).. <i>Blood</i> , 2007, 110, 1490-1490.	1.4	3
198	Hepatic and renal plasma cell lesions in a patient with multiple myeloma in hematological remission. <i>Anticancer Research</i> , 2007, 27, 571-4.	1.1	5

#	ARTICLE	IF	CITATIONS
199	Treatment strategies for pediatric nodular lymphocyte predominant Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 1450-1451.	1.3	3
200	Impact of LMP-1 expression on clinical outcome in age-defined subgroups of patients with classical Hodgkin lymphoma. <i>Blood</i> , 2006, 107, 1240-1241.	1.4	10
201	The combination of the load/force balance and the frequency/tidal volume can predict weaning outcome. <i>Intensive Care Medicine</i> , 2006, 32, 684-691.	8.2	25
202	Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab. <i>European Journal of Haematology</i> , 2006, 77, 300-303.	2.2	47
203	Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. <i>European Journal of Haematology</i> , 2006, 77, 387-394.	2.2	37
204	Immunotherapeutic and Immunoregulatory Drugs in Haematologic Malignancies. <i>Current Topics in Medicinal Chemistry</i> , 2006, 6, 1657-1686.	2.1	12
205	Rituximab-CHOP (R-CHOP) and Radiotherapy (RT) for Primary Mediastinal Large B-Cell Lymphoma (PMLBCL).. <i>Blood</i> , 2006, 108, 2745-2745.	1.4	4
206	Z-Guggulsterone Downregulates Survivin and Induces Cell Death in Large B Cell Lymphoma Cells In Vitro.. <i>Blood</i> , 2006, 108, 4752-4752.	1.4	0
207	Serum Free Light Chain Ratio (FLCR) at Diagnosis Constitute a Powerful Prognostic Factor of Survival in Multiple Myeloma (MM).. <i>Blood</i> , 2006, 108, 3522-3522.	1.4	0
208	Efficacy of Rituximab in Hairy Cell Leukemia.. <i>Blood</i> , 2006, 108, 4719-4719.	1.4	0
209	B-Chronic Lymphoproliferative Disorders (BCLD) Presenting with Splenomegaly: Differential Diagnosis and Outcome.. <i>Blood</i> , 2006, 108, 4655-4655.	1.4	0
210	Evaluation of Microsatellite Instability in Gastric MALT Lymphomas.. <i>Blood</i> , 2006, 108, 4625-4625.	1.4	0
211	Long Term Follow up of Hairy Cell Leukemia (HCL) Patients (PTS) Treated with Interferon-Alpha (IFN- α). The Importance of Maintenance.. <i>Blood</i> , 2006, 108, 4718-4718.	1.4	0
212	Pure infradiaphragmatic Hodgkin's lymphoma. Clinical features, prognostic factor and comparison with supradiaphragmatic disease. <i>Haematologica</i> , 2006, 91, 32-9.	3.5	17
213	Is loaded breathing an inflammatory stimulus?. <i>Current Opinion in Critical Care</i> , 2005, 11, 1-9.	3.2	11
214	Development and validation of a clinical prediction rule for bone marrow involvement in patients with Hodgkin lymphoma. <i>Blood</i> , 2005, 105, 1875-1880.	1.4	61
215	Bench-to-bedside review: weaning failure--should we rest the respiratory muscles with controlled mechanical ventilation?. <i>Critical Care</i> , 2005, 10, 204.	5.8	26
216	Differential Diagnosis of Waldenström's Macroglobulinemia and Other B-Cell Disorders. <i>Clinical Lymphoma and Myeloma</i> , 2005, 5, 235-240.	2.1	31

#	ARTICLE	IF	CITATIONS
217	Reversible dilated cardiomyopathy associated with amphotericin B treatment. <i>International Journal of Antimicrobial Agents</i> , 2005, 25, 444-447.	2.5	16
218	Excellent Outcome with Rituximab-CHOP (R-CHOP) Combined with Radiotherapy (RT) in Primary Mediastinal Large B-Cell Lymphoma (PMLBCL).. <i>Blood</i> , 2005, 106, 935-935.	1.4	4
219	Serum Levels of OPG and MIP-1 β in Untreated Multiple Myeloma Patients. Correlations with Staging, Survival and Bone Disease.. <i>Blood</i> , 2005, 106, 5074-5074.	1.4	0
220	Rituximab Monotherapy Is an Effective Treatment for Splenic Marginal Zone B-Cell Lymphomas (SMZL).. <i>Blood</i> , 2005, 106, 4800-4800.	1.4	0
221	Retrospective Analysis of 41 Consecutive Patients with Non Gastrointestinal (GI) Extranodal Marginal Zone B-Cell Lymphoma (EMZL): Correlation of Clinical Characteristics and Outcome with Disease Localization.. <i>Blood</i> , 2005, 106, 4785-4785.	1.4	0
222	Molecular Analysis of the VH Gene Usage in a Familial Case of Waldenström's Macroglobulinemia.. <i>Blood</i> , 2005, 106, 1005-1005.	1.4	0
223	Topoisomerase II β (TopoII β) Expression in Hodgkin's Lymphoma (HL): Correlations with Conventional and Biological Markers and Prognostic Significance under Treatment with ABVD or Equivalent Regimens with or without Radiotherapy (RT).. <i>Blood</i> , 2005, 106, 967-967.	1.4	0
224	Bortezomib in Patients with Relapsed-Refractory Multiple Myeloma (MM). Clinical Observations.. <i>Blood</i> , 2005, 106, 5193-5193.	1.4	0
225	Serum Soluble Syndecan-1 Levels at Diagnosis Constitute an Independent Prognostic Factor of Survival in Myeloma That May Further Differentiate Patients within the ISS Stages.. <i>Blood</i> , 2005, 106, 3404-3404.	1.4	0
226	Serum levels of soluble syndecan-1 in Hodgkin's lymphoma. <i>Anticancer Research</i> , 2005, 25, 4743-6.	1.1	31
227	The immune response to resistive breathing: Implications for respiratory failure. <i>Clinical Intensive Care: International Journal of Critical & Coronary Care Medicine</i> , 2004, 15, 131-144.	0.1	0
228	Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. <i>European Journal of Haematology</i> , 2004, 72, 252-258.	2.2	27
229	Ida ⁺ FLAG plus imatinib mesylate-induced molecular remission in a patient with chemoresistant Ph ^{<sup>+</sup> acute myeloid leukemia. <i>European Journal of Haematology</i>, 2004, 72, 58-60.}	2.2	20
230	Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 765-781.	0.8	22
231	Elevated Serum Levels of IL-10 are Associated with Inferior Progression-Free Survival in Patients with Hodgkin's Disease Treated with Radiotherapy. <i>Leukemia and Lymphoma</i> , 2004, 45, 2085-2092.	1.3	43
232	Adult T-Cell Leukemia/Lymphoma (ATLL): Report of Two Fully Documented Hellenic Patients. <i>Leukemia and Lymphoma</i> , 2004, 45, 715-721.	1.3	7
233	Interferon Alpha-2B (IFN- α) Is an Effective Agent for the Treatment of Primary Cutaneous T- and B-Cell Lymphoma.. <i>Blood</i> , 2004, 104, 2643-2643.	1.4	43
234	Serum Soluble Syndecan-1 Levels Correlate with Erythropoietin and Inversely with Hemoglobin Levels in Untreated Anaemic Myeloma Patients: Possible Role of Syndecan-1 in the Mechanisms of Chronic Anaemia.. <i>Blood</i> , 2004, 104, 4882-4882.	1.4	0

#	ARTICLE	IF	CITATIONS
235	Lymphoma of the Oral Cavity. A Rare Entity with Favorable Prognosis. Ten-Year Experience of a Single Hematology Unit.. Blood, 2004, 104, 4595-4595.	1.4	0
236	B-Chronic Lymphocytic Leukemia (B-CLL), Small Lymphocytic Lymphoma (SLL) and Waldenstrom's Macroglobulinemia (MW): A Comparative Fish Analysis.. Blood, 2004, 104, 4801-4801.	1.4	0
237	The immune response to resistive breathing: Implications for respiratory failure. Clinical Intensive Care: International Journal of Critical & Coronary Care Medicine, 2004, 15, 131-144.	0.1	0
238	Differential diagnosis of Waldenstrom's macroglobulinemia from other low-grade B-cell lymphoproliferative disorders. Seminars in Oncology, 2003, 30, 201-205.	2.2	18
239	A Randomized Trial Comparing Intensified CNOP vs. CHOP in Patients with Aggressive Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 2003, 44, 635-644.	1.3	9
240	Antioxidants attenuate the plasma cytokine response to exercise in humans. Journal of Applied Physiology, 2003, 94, 1025-1032.	2.5	149
241	Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma: associations with presenting features, serum interleukin 10 levels, and clinical outcome. Clinical Cancer Research, 2003, 9, 2114-20.	7.0	56
242	Correspondence re: M. Provencio, et al. the topoisomerase IIa expression correlates with survival in patients with advanced Hodgkin's lymphoma. Clin. Cancer Res., 9: 1406-1411, 2003. Clinical Cancer Research, 2003, 9, 5430-1; author reply 5431.	7.0	2
243	Strenuous Resistive Breathing Induces Plasma Cytokines. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 1572-1578.	5.6	64
244	BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood, 2002, 100, 3935-3941.	1.4	90
245	CD20 Expression in Hodgkin and Reed-Sternberg Cells of Classical Hodgkin's Disease: Associations With Presenting Features and Clinical Outcome. Journal of Clinical Oncology, 2002, 20, 1278-1287.	1.6	79
246	The splenic form of mantle cell lymphoma. European Journal of Haematology, 2002, 68, 12-21.	2.2	45
247	Hodgkin's lymphoma in first relapse following chemotherapy or combined modality therapy: analysis of outcome and prognostic factors after conventional salvage therapy. European Journal of Haematology, 2002, 68, 289-298.	2.2	8
248	B-chronic lymphocytic leukemia: practical aspects. Hematological Oncology, 2002, 20, 103-146.	1.7	41
249	BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: correlation with clinical outcome. Clinical Cancer Research, 2002, 8, 488-93.	7.0	20
250	Downstaging Rai stage III B-chronic lymphocytic leukemia patients with the administration of recombinant human erythropoietin. Haematologica, 2002, 87, 500-6.	3.5	16
251	The prognostic significance of beta(2)-microglobulin in patients with Hodgkin's lymphoma. Haematologica, 2002, 87, 701-8; discussion 708.	3.5	34
252	Pegylated liposomal doxorubicin in the CHOP regimen for older patients with aggressive (stages III/IV) non-Hodgkin's lymphoma. Anticancer Research, 2002, 22, 1845-8.	1.1	28

#	ARTICLE	IF	CITATIONS
253	Uremic pericarditis with tamponade following prolonged continuous hemofiltration. Intensive Care Medicine, 2001, 27, 1958-1959.	8.2	4
254	Correction of Disease Related Anaemia of B-Chronic Lymphoproliferative Disorders by Recombinant Human Erythropoietin: Maintenance is Necessary to Sustain Response. Leukemia and Lymphoma, 2000, 40, 141-147.	1.3	23
255	Contribution of Pain to Inspiratory Muscle Dysfunction after Upper Abdominal Surgery. American Journal of Respiratory and Critical Care Medicine, 2000, 161, 1372-1375.	5.6	68
256	EBVD Combination Chemotherapy Plus Low Dose Involved Field Radiation is a Highly Effective Treatment Modality for Early Stage Hodgkin's Disease. Leukemia and Lymphoma, 2000, 37, 131-143.	1.3	16